Sinalização PI3K/Akt/mTOR
Os inibidores da sinalização PI3K/Akt/mTOR são compostos que têm como alvo as vias da fosfoinositídeo 3-quinase (PI3K), da quinase Akt e do alvo da rapamicina em mamíferos (mTOR). Essas vias são reguladores críticos do crescimento celular, sobrevivência, metabolismo e autofagia, tornando-os alvos-chave na pesquisa de câncer e distúrbios metabólicos. A inibição dessas vias pode ajudar a controlar o crescimento e a proliferação tumoral, oferecendo estratégias terapêuticas potenciais para vários tipos de câncer e outras doenças caracterizadas por sinalização celular desregulada. Na CymitQuimica, oferecemos uma ampla seleção de inibidores de alta qualidade de PI3K/Akt/mTOR para apoiar sua pesquisa em oncologia, sinalização celular e doenças metabólicas.
Subcategorias de "Sinalização PI3K/Akt/mTOR"
- AMPK(158 produtos)
- ATM/ATR(71 produtos)
- DNA-PK(51 produtos)
- EGFR(572 produtos)
- MELK(7 produtos)
- PDK(9 produtos)
- PI3K(242 produtos)
- S6 Quinase(9 produtos)
- gsk-3(112 produtos)
- mTOR(144 produtos)
Exibir 2 mais subcategorias
Foram encontrados 1038 produtos de "Sinalização PI3K/Akt/mTOR"
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
Epitinib succinate
CAS:<p>Epitinib succinate (HMPL-813 succinate) is an orally active and brain penetration EGFR tyrosine kinase inhibitor and can be used in studies about cancer.</p>Fórmula:C28H32N6O6Pureza:98.02% - 99.79%Cor e Forma:SolidPeso molecular:548.59JR-AB2-011
CAS:<p>JR-AB2-011: selective mTORC2 inhibitor, IC50 = 0.36μM, blocks Rictor-mTOR, Ki = 0.19μM, cytotoxic in glioblastoma.</p>Fórmula:C17H14Cl2FN3OSPureza:98.33% - 98.33%Cor e Forma:SolidPeso molecular:398.28Falnidamol
CAS:<p>Falnidamol (BIBX 1382), an oral selective EGFR inhibitor, IC50 3 nM, weak on ErbB2 and others, anti-cancer pyrimido-pyrimidine.</p>Fórmula:C18H19ClFN7Pureza:98.816%Cor e Forma:SolidPeso molecular:387.84EGFR-IN-9
CAS:<p>EGFR-IN-9 is a potent EGFR kinase inhibitor with IC50s of 7 nM, 28 nM for the wild type EGFR kinase and double mutant EGFR kinase (L858R/T790M).</p>Fórmula:C29H24N4O3Pureza:99.8%Cor e Forma:SolidPeso molecular:476.53Cloperastine fendizoate
CAS:<p>Cloperastine fendizoate (Hustazol) inhibits the hERG K+ currents in a concentration-dependent manner (IC50: 27 nM).</p>Fórmula:C40H38ClNO5Pureza:99.97%Cor e Forma:SolidPeso molecular:648.19GS-9901
CAS:<p>GS-9901 is a selective, orally active and potent PI3Kδ inhibitor (IC50: 1 nM) for the study of non-Hodgkin's lymphoma and chronic lymphocytic leukemia.</p>Fórmula:C22H17ClFN9OPureza:98.60% - 99.92%Cor e Forma:SolidPeso molecular:477.88EGFR-IN-99
CAS:<p>EGFR-IN-99 (JBJ-03-142-02) is an EGFR and HER2 Exon 20 insertion mutation inhibitor for the study of non-small cell lung cancer (NSCLC).</p>Fórmula:C25H22FN7O3Pureza:97.75%Cor e Forma:SolidPeso molecular:487.49A-935142
CAS:<p>A-935142 enhances hERG (Kv 11.1) channels, slows inactivation, promotes activation, and shortens repolarization.</p>Fórmula:C18H19F3N2O2Pureza:98.97% - 99.91%Cor e Forma:SolidPeso molecular:352.35EMI1
CAS:<p>EMI1 targets mutated EGFR in drug-resistant NSCLC research.</p>Fórmula:C20H18N2O3Pureza:99.96%Cor e Forma:SolidPeso molecular:334.37PD 174265
CAS:<p>PD 174265 is an effective, selective and reversible inhibitor of epidermal growth factor receptor (EGFR) with an IC50 of 0.45 nM.</p>Fórmula:C17H15BrN4OPureza:99.51%Cor e Forma:SolidPeso molecular:371.23GSK-3β inhibitor 11
CAS:<p>GSK-3β inhibitor 11 (compound 21) is a potent inhibitor of glycogen synthase kinase-3β (GSK-3β) with an inhibitory concentration (IC50) of 10.02 μM.</p>Fórmula:C20H15N3O4SPureza:97.33%Cor e Forma:SolidPeso molecular:393.42Tyrphostin A25
CAS:<p>Tyrphostin A25 (Tyrphostin AG 82) is a specific EGFR tyrosine kinase inhibitor and GPR35 agonist with an IC50 value of 0.94 μM for GPR35 and an EC50 value of 5.</p>Fórmula:C10H6N2O3Pureza:98.76%Cor e Forma:Yellow Green Powder /Off-White SolidPeso molecular:202.17SKLB 1028
CAS:<p>SKLB 1028, an oral EGFR/FLT3/Abl inhibitor, excels in AML and CML with Abl mutations.</p>Fórmula:C24H29N9Pureza:99.90% - >99.99%Cor e Forma:SolidPeso molecular:443.55CGP77675
CAS:<p>CGP77675 (ZINC1488120) is a potent and selective inhibitor of Src family kinase with IC50s of 5-20 and 40 nM for the phosphorylation of peptide substrates and</p>Fórmula:C26H29N5O2Pureza:99.66%Cor e Forma:SolidPeso molecular:443.54BIP-135
CAS:<p>BIP-135 is a potent and selective ATP-competitive GSK-3 inhibitor.</p>Fórmula:C21H13BrN2O3Pureza:99.93%Cor e Forma:SolidPeso molecular:421.24ARN25068
CAS:<p>ARN25068 inhibits GSK-3β, FYN, DYRK1A kinases; acts in sub-micromolar range; combats tau hyperphosphorylation.</p>Fórmula:C19H18N6SPureza:99.75%Cor e Forma:SolidPeso molecular:362.45LY 456236 hydrochloride
CAS:<p>LY 456236 hydrochloride (MPMQ hydrochloride) is an mGlu1 receptor antagonist with an ic50 value of 143 nM.</p>Fórmula:C16H16ClN3O2Pureza:99.95%Cor e Forma:SolidPeso molecular:317.77GSK-3 Inhibitor XIII
CAS:<p>GSK-3 InhibitorXIII, an ATP-competitive GSK-3 inhibitor (Ki: 24 nM), can be used to study diabetes and obesity.</p>Fórmula:C18H15N5Pureza:99.85% - 99.86%Cor e Forma:SolidPeso molecular:301.35Larotinib
CAS:<p>Larotinib is an orally active, potent, and broad-spectrum tyrosine kinase inhibitor (TKI) with an IC50 of 0.6 nM for EGFR.</p>Fórmula:C24H26ClFN4O4Pureza:98.45%Cor e Forma:SolidPeso molecular:488.94AZ044
CAS:<p>AZ044 is a potent, selective inhibitor of type III phosphatidylinositol-4-kinase alpha-subtype (PI4KIIIalpha).</p>Fórmula:C24H27N3O3SPureza:99.5%Cor e Forma:SolidPeso molecular:437.55YKL-06-062
CAS:<p>YKL-06-062 is a second-generation salt-inducible kinase (SIK) inhibitor that inhibits SIK1, SIK2 and SIK3 with IC50s of 2.12 nM, 1.40 nM and 2.86 nM.</p>Fórmula:C31H39N7OPureza:99.87%Cor e Forma:SolidPeso molecular:525.69PQR514
CAS:<p>PQR514: more potent pan-PI3K inhibitor than predecessor PQR309, exhibits strong anticancer activity in vitro and in OVCAR-3 model.</p>Fórmula:C16H20F2N8O2Pureza:98.77% - 99.19%Cor e Forma:SolidPeso molecular:394.38MELK-8a hydrochloride
CAS:<p>MELK-8a hydrochloride is a potent inhibitor of maternal embryonic leucine zipper kinase (MELK, IC50 = 2 nM). </p>Fórmula:C25H33ClN6OPureza:99.87%Cor e Forma:SolidPeso molecular:469.02PKI-166
CAS:<p>PKI-166: oral EGF-R tyrosine kinase inhibitor (IC50: 0.7 nM), halts growth & spread of many human cancers, including pancreatic.</p>Fórmula:C20H18N4OPureza:99.2%Cor e Forma:SolidPeso molecular:330.38RS1-PDK1 inhibitor
CAS:<p>RS1-PDK1 inhibitor (RS 1) is a selective inhibitor of the protein kinase PDK1 that can be used to treat and prevent disease or disorders.</p>Fórmula:C15H9ClN2O2S3Pureza:98.12%Cor e Forma:SolidPeso molecular:380.89TGX-115
CAS:<p>TGX-115 inhibits PI 3-K p110β (IC50=0.13μM) & p110δ (IC50=0.63μM), treats various cardiovascular diseases.</p>Fórmula:C20H20N2O3Pureza:99.48%Cor e Forma:SolidPeso molecular:336.38Rezivertinib
CAS:<p>Rezivertinib (BPI-7711) is an EGFR inhibitor with antitumor activity and can be used to study central nervous system diseases.</p>Fórmula:C27H30N6O3Pureza:99.26% - 99.89%Cor e Forma:SolidPeso molecular:486.57NVP-BAG956
CAS:<p>NVP-BAG956 is an ATP-competitive PI3K inhibitor (IC50s: 34/56/112/444 nM for PI3Kδ/PI3Kα/PI3Kγ/PI3Kβ).</p>Fórmula:C28H21N5Pureza:99.25% - 99.80%Cor e Forma:SolidPeso molecular:427.5(R)-(-)-Rolipram
CAS:<p>(R)-(-)-Rolipram ((-)-Rolipram) is an R-enantiomer of Rolipram which is a PDE4 inhibitor.</p>Fórmula:C16H21NO3Pureza:99.54%Cor e Forma:SolidPeso molecular:275.34PF-249
CAS:<p>PF-249 (PF-06685249) is a β1-selective AMPK with an EC50 of 12 nM for AMPK α1β1γ1 and can be used in studies about diabetic nephropathy.</p>Fórmula:C17H16ClN3O3Pureza:97.01%Cor e Forma:SolidPeso molecular:345.78SRX3207
CAS:<p>SRX3207 is an inhibitor of Syk and PI3K and relieves tumor immunosuppression.</p>Fórmula:C29H29N7O3SPureza:99.85%Cor e Forma:SolidPeso molecular:555.65GSK-3β inhibitor 2
CAS:<p>GSK-3β inhibitor 2 (5-Thiazolecarboxamide,2-[2-[(cyclopropylcarbonyl)amino]-4-pyridinyl]-4-methoxy-) is a BBB-crossing and selective inhibitor of GSK-3β (IC50</p>Fórmula:C14H14N4O3SPureza:99.08%Cor e Forma:SolidPeso molecular:318.35YLF-466D
CAS:<p>YLF-466D (C24) is a newly developed AMPK activator, which inhibits platelet aggregation.</p>Fórmula:C29H20ClNO3Pureza:97.74%Cor e Forma:SolidPeso molecular:465.93Sunvozertinib
CAS:<p>Sunvozertinib (DZD9008) is a potent ErbBs and BTK inhibitor, with inhibitory effects on EGFR, Her2.Cost-effective and quality-assured.</p>Fórmula:C29H35ClFN7O3Pureza:98.11% - 99.63%Cor e Forma:SolidPeso molecular:584.08ABC1183
CAS:<p>ABC1183, an oral diaminothiazole, inhibits GSK3α/β, CDK9, hinders cancer cell growth, induces G2/M arrest, and modulates phosphorylation.</p>Fórmula:C18H14N4OSPureza:98.92%Cor e Forma:SolidPeso molecular:334.39(Z)-RG-13022
CAS:<p>(Z)-RG-13022 is a tyrosine kinase (TK) inhibitor that preferentially inhibits the TK activity of the EGF receptor, restricting the EGF-stimulated growth of cultured cells. It demonstrates an IC50 of 11 μM for DNA synthesis in HN5 cells, showcasing thrice the potency of its isomer, (E)-RG-13022 (IC50 = 38 μM). This compound is applied in breast cancer cell research [1] [2].</p>Fórmula:C16H14N2O2Cor e Forma:SolidPeso molecular:266.29PI3Kδ-IN-17
CAS:<p>PI3Kδ-IN-17 (Compound S5) is a potent PI3K δ inhibitor, exhibiting an IC50 value of 2.82 nM and demonstrates significant efficacy in suppressing the</p>Fórmula:C23H24F3N7O2Pureza:98%Cor e Forma:SolidPeso molecular:487.48MTI-31
CAS:<p>MTI-31 (LXI-15029) is a potent oral mTORC1/2 inhibitor with a Kd of 0.20 nM, >5,000-fold selectivity, and an IC50 of 39 nM.</p>Fórmula:C26H30N6O3Pureza:99.97%Cor e Forma:SolidPeso molecular:474.55PI3K/mTOR Inhibitor-14
CAS:<p>PI3K/mTOR Inhibitor-14 (compound Y-2) serves as a dual inhibitor of PI3K and mTOR, exhibiting IC50 values of 171.4 nM and 10.1 nM , respectively, and</p>Fórmula:C28H30N8O3SPureza:98%Cor e Forma:SolidPeso molecular:558.66PI3K/mTOR Inhibitor-7
CAS:<p>Potent PI3K/mTOR inhibitor, 4.7x stronger than gedatolisib; IC50: 1.4 μM (PI3K), 0.3 μM (mTOR); impacts PI3K/Akt/mTOR pathway; research in cancer.</p>Fórmula:C29H33N9O4Cor e Forma:SolidPeso molecular:571.63LAS191954
CAS:<p>LAS191954 is a selective, potent and orally active PI3Kδ inhibitor for inflammatory diseases treatment(IC50 : 2.6 nM).</p>Fórmula:C20H15N9OPureza:98%Cor e Forma:SolidPeso molecular:397.39MIPS-21335
CAS:<p>MIPS-21335 is a potent PI3KC2α inhibitor with an IC50 value of 7 nM and additionally exhibits inhibitory activity against PI3KC2β, p110α, p110β, and p110δ with</p>Fórmula:C24H21N7O5Pureza:98%Cor e Forma:SolidPeso molecular:487.47MP7
CAS:<p>MP7 (PDK1 inhibitor) is a inhibitor of phosphoinositide-dependent kinase-1 (PDK1).</p>Fórmula:C28H22F2N4O4Pureza:99.84% - 99.89%Cor e Forma:SolidPeso molecular:516.5ZL-2201
CAS:<p>ZL-2201 is a potent inhibitor of DNA-PK, demonstrating an IC50 value of 1 nM.</p>Fórmula:C20H25N9O5SPureza:98%Cor e Forma:SolidPeso molecular:503.54EGFR-IN-1
CAS:<p>EGFR-IN-1: an oral, irreversible EGFR inhibitor targeting L858R/T790M mutations with high selectivity, showing potent antitumor effects.</p>Fórmula:C28H30N6O4Pureza:98%Cor e Forma:SolidPeso molecular:514.58MSC2360844
CAS:<p>MSC2360844 is a potent, orally active and selective inhibitor of PI3Kδ(IC50 of 145 nM).</p>Fórmula:C26H27FN4O5SPureza:99.54% - 99.9%Cor e Forma:SolidPeso molecular:526.58SAR-260301
CAS:<p>SAR-260301 is an orally available and selective inhibitor of PI3Kβ (IC50: 23 nM).</p>Fórmula:C19H22N4O3Pureza:99.74%Cor e Forma:SolidPeso molecular:354.4EGFR-IN-33
CAS:<p>EGFR-IN-33, a low-toxicity acrylamide, inhibits EGFR, aiding against cancer, especially NSCLC (from WO2021185348A1, comp. 13).</p>Fórmula:C26H25ClN6O2Cor e Forma:SolidPeso molecular:488.97PIK-inhibitors
CAS:<p>PIK-inhibitors (MDK34597) is a pan PI3K inhibitors, an analog of PI-103.</p>Fórmula:C19H17N5O2Pureza:96.98%Cor e Forma:SolidPeso molecular:347.37EGFR-IN-71
CAS:<p>EGFR-IN-71 is a potent inhibitor of epidermal growth factor receptor (EGFR) (IC50= 3.7 μM). EGFR-IN-71 has research value in chordoma.</p>Fórmula:C16H9ClIN3Cor e Forma:SolidPeso molecular:405.62PI5P4K-β-IN-1
CAS:<p>PI5P4K-β-IN-1 (compound vs1) is a potent PI5P4K-β inhibitor with an IC50 of 0.80 μM [1].</p>Fórmula:C23H17Cl2N3O2Cor e Forma:SolidPeso molecular:438.31BGB-102
CAS:<p>BGB-102 (JNJ-26483327) is a kinase inhibitor targeting FLT3 and YES1 and an antagonist targeting EGFR and VEGFR3.</p>Fórmula:C22H25BrN4O2Pureza:99.02%Cor e Forma:SolidPeso molecular:457.36Tenalisib R Enantiomer
CAS:<p>Tenalisib R Enantiomer is an R enantiomer of Tenalisib .</p>Fórmula:C23H18FN5O2Pureza:98%Cor e Forma:SolidPeso molecular:415.42JND3229
CAS:<p>JND3229 inhibits EGFRC797S; IC50: 5.8-30.5 nM; halts cell growth; effective in non-small cell lung cancer study.</p>Fórmula:C33H41ClN8O2Pureza:98.75%Cor e Forma:SolidPeso molecular:617.18mTOR inhibitor-11
CAS:<p>mTOR inhibitor-11 (Compound 9) is a brain-penetrant compound capable of inhibiting mTOR with an IC50 of 21 nM for pS6.</p>Fórmula:C21H26N6O2Pureza:98%Cor e Forma:SolidPeso molecular:394.47DNA-PK-IN-10
CAS:<p>DNA-PK-IN-10 is a DNA-PK inhibitor utilized in the research of breast cancer and non-small cell lung cancer [1].</p>Fórmula:C25H28N6O2Pureza:98%Cor e Forma:SolidPeso molecular:444.53BRD5648
CAS:<p>BRD5648 ((R)-BRD0705) is an inactive (R)-enantiomer of BRD0705.</p>Fórmula:C20H23N3OPureza:99.89%Cor e Forma:SolidPeso molecular:321.42GNE-490
CAS:<p>GNE-490 is an effective inhibitor of pan-PI3K with IC50s of 3.5 nM, 25 nM, 5.2 nM, 15 nM for PI3Kα, PI3Kβ, PI3Kδ and PI3Kγ, respectively.</p>Fórmula:C18H22N6O2SPureza:99.77%Cor e Forma:SolidPeso molecular:386.47TCS 21311
CAS:<p>TCS 21311 (NIBR3049) selectively inhibits JAK3 (IC50: 8 nM) and PKCα/θ & GSK3β; >100x selective over JAK1, JAK2, TYK2.</p>Fórmula:C27H25F3N4O4Pureza:99.39% - ≥98%Cor e Forma:SolidPeso molecular:526.51LDHA/PDKs-IN-1
CAS:<p>Compound 20e inhibits PDKs (IC50: 0.8 μM) & LDHA (IC50: 0.15 μM), halts A549 cell growth, lowers lactate, boosts oxygen use.</p>Fórmula:C19H21FN2O4Cor e Forma:SolidPeso molecular:360.38(Rac)-BRD0705
CAS:<p>(Rac)-BRD0705 is a less active racemate of BRD0705. BRD0705 is an effective and selective inhibitor of GSK3α.</p>Fórmula:C20H23N3OPureza:99.7%Cor e Forma:SolidPeso molecular:321.42MS 154
CAS:<p>MS 154 is a potent PROTAC® targeting mutant EGFR in lung cancer, sparing WT-EGFR; effective in mice, with DC50 of 11-25 nM.</p>Fórmula:C46H54ClFN8O8Cor e Forma:SolidPeso molecular:901.42WYE-23
CAS:<p>WYE-23 is an inhibitor of mammalian target of rapamycin (mTOR).</p>Fórmula:C26H32N8O4Cor e Forma:SolidPeso molecular:520.58T-00127_HEV1
CAS:<p>T-00127_HEV1 is an inhibitor of phosphatidylinositol 4-kinase III beta(PI4KIIIβ, IC50 = 60 nM).</p>Fórmula:C22H29N5O3Pureza:99.89%Cor e Forma:SolidPeso molecular:411.5mTOR inhibitor 9d
CAS:<p>mTOR inhibitor 9d is a dual inhibitor of the protein kinases mTOR and PI3K with an mTOR IC50 value of 0.31 nm, and can be used for the treatment of leukemia,</p>Fórmula:C21H23N5O3SPureza:99.08%Cor e Forma:SoildPeso molecular:425.517β-Hydroxywortmannin
CAS:<p>17β-Hydroxywortmannin is an orally active phosphatidylinositol-3-kinase (PI-3-kinase) inhibitor, exhibiting an IC50 of 0.5 nM and notably suppresses osteoclast resorption at an IC50 of 10 nM. Additionally, it demonstrates antitumor activity.</p>Fórmula:C23H26O8Cor e Forma:SolidPeso molecular:430.45EGFR-IN-74
<p>EGFR-IN-74 is a potent inhibitor targeting EGFR, specifically effective against the L858R/T790M mutations, exhibiting an IC50 value of 138 nM.</p>Fórmula:C32H28BrF3N6O4SCor e Forma:SolidPeso molecular:729.57mTOR inhibitor 9b
CAS:<p>mTOR inhibitor 9b is an enzyme inhibitor of protein kinase mTOR he phosphatidylinositol 3-kinase PIK3CA with IC50s of 0.76 nm and 1.262 µM, respectively.mTOR</p>Fórmula:C21H23N5O2SPureza:99.52%Cor e Forma:SoildPeso molecular:409.5Dezapelisib
CAS:<p>Dezapelisib, an oral delta PI3K inhibitor, blocks PIP3 production and PI3K/AKT pathway, hindering tumor cell growth and survival.</p>Fórmula:C20H16FN7OSCor e Forma:SolidPeso molecular:421.45Labuxtinib
CAS:<p>Labutinib is a selective inhibitor of the c-kit tyrosine kinase [1].</p>Fórmula:C20H16FN5O2Pureza:99.77%Cor e Forma:SolidPeso molecular:377.37SU-11752
CAS:<p>SU-11752 selectively inhibits DNA-PK by competing with ATP, enhances ionizing radiation sensitivity without affecting cell cycle or ATM activity.</p>Fórmula:C26H27N3O5SCor e Forma:SolidPeso molecular:493.57PAT-505
CAS:<p>PAT-505 is an autologous epidermal growth factor inhibitor.</p>Fórmula:C23H18ClF2N3O2SPureza:98.84%Cor e Forma:SolidPeso molecular:473.92BMS-599626 Hydrochloride
CAS:<p>BMS-599626 HCl (AC480 HCl) is an oral inhibitor of HER1, HER2, HER4 kinases, potentially blocking tumor growth. IC50: 22/32/190 nM.</p>Fórmula:C27H28ClFN8O3Pureza:99.98%Cor e Forma:SolidPeso molecular:567.01ZLN024
CAS:<p>ZLN024 is an activator of AMPK allosteric.</p>Fórmula:C13H13BrN2OSPureza:99.751%Cor e Forma:SolidPeso molecular:325.22PI3K/mTOR Inhibitor-1
CAS:<p>PI3K/mTOR Inhibitor-1 is a potent, orally bioavailable dual inhibitor of PI3K/mTOR (PI3Kα/PI3Kβ/PI3Kδ/PI3Kγ/mTOR with IC50s of 20/376/204/46/186 nM)</p>Fórmula:C18H22FN5O3SPureza:98%Cor e Forma:SolidPeso molecular:407.46CAL-130 Racemate
CAS:<p>CAL-130 Racemate is the racemate of CAL-130. CAL-130 is a PI3Kδ and PI3Kγ inhibitor (IC50s: 1.3 and 6.1 nM).</p>Fórmula:C23H22N8OPureza:98%Cor e Forma:SolidPeso molecular:426.47HKI-357
CAS:<p>HKI-357 irreversibly inhibits EGFR/ERBB2 (IC50: 34/33 nM), blocks EGFR Y1068 autophosphorylation, and AKT/MAPK phosphorylation.</p>Fórmula:C31H29ClFN5O3Pureza:99.91%Cor e Forma:SolidPeso molecular:574.05PF-06459988
CAS:<p>PF-06459988 is a novel, effective, orally active, irreversible, and selective epidermal growth factor receptor (EGFR) mutant inhibitor.</p>Fórmula:C19H22ClN7O3Pureza:98%Cor e Forma:SolidPeso molecular:431.88mTOR inhibitor-3
CAS:<p>mTOR inhibitor-3 is a selective mTOR inhibitor (Ki= 1.5 nM). mTOR inhibitor-3 inhibits mTORC1 and mTORC2 in cellular and in vivo experiments.</p>Fórmula:C25H30N8O2Pureza:99% - 99.64%Cor e Forma:SolidPeso molecular:474.56Zandelisib
CAS:<p>Zandelisib is an inhibitor of phosphatidylinositol 3-kinase (PI3K)(p110δ, IC50 of 3.5 nM), and with antineoplastic activity.</p>Fórmula:C31H38F2N8OPureza:99.88%Cor e Forma:SolidPeso molecular:576.68Alpelisib hydrochloride
CAS:<p>Alpelisib hydrochloride (BYL-719) is an oral, selective PI3Kα inhibitor with anticancer properties.</p>Fórmula:C19H23ClF3N5O2SPureza:98%Cor e Forma:SolidPeso molecular:477.93PI3Kδ-IN-1
CAS:<p>PI3Kδ-IN-1 is an efficacious PI3Kδ inhibitor (IC50 of 1.7 nM).</p>Fórmula:C22H20F3N7O2Pureza:99.85%Cor e Forma:SolidPeso molecular:471.44EGFR-IN-29
CAS:<p>EGFR-IN-29 is a potent EGFR inhibitor.</p>Fórmula:C36H46BrN8O2PCor e Forma:SolidPeso molecular:733.685-Iodo-indirubin-3'-monoxime
CAS:<p>5-Iodo-indirubin-3'-monoxime is a potent GSK-3β, CDK5/P25 and CDK1/cyclin B inhibitor, competing with ATP for binding to the catalytic site of the kinase (IC50s</p>Fórmula:C16H10IN3O2Cor e Forma:SolidPeso molecular:403.17Ampkinone
CAS:<p>Ampkinone is an indirect AMPK activator.</p>Fórmula:C31H23NO6Pureza:98%Cor e Forma:SolidPeso molecular:505.52BPIQ-I
CAS:<p>BPIQ-I (PD 159121), an ATP-competitive EGFR tyrosine kinase inhibitor, exhibits potent anti-proliferative activity.</p>Fórmula:C16H12BrN5Cor e Forma:SolidPeso molecular:354.2LDHA/PDKs-IN-2
CAS:<p>Compound 20k is a dual LDHA/PDKs inhibitor; IC50: 0.7/1.6 μM. It boosts O2 use, cuts lactate, and slows A549 cancer cell growth (EC50: 15.7 μM).</p>Fórmula:C17H20N2O5Cor e Forma:SolidPeso molecular:332.35PI3K/mTOR Inhibitor-6
CAS:<p>Potent, stable PI3K/mTOR Inhibitor-6 surpasses gedatolisib in gastric fluid; 10 μM hinders PI3K/Akt/mTOR pathway, aids cancer research.</p>Fórmula:C30H34N10O4Cor e Forma:SolidPeso molecular:598.66NVP-QAV-572
CAS:<p>NVP-QAV-572 is a inhibitor of PI3K(IC50 of 10 nM).</p>Fórmula:C17H19F2N7O3S2Pureza:98%Cor e Forma:SolidPeso molecular:471.5Lifirafenib
CAS:<p>Lifirafenib (Beigene-283) is a potent inhibitor of RAF family kinases and EGFR in biochemical assays with IC50 of 23, 29 and 495 nM for the recombinant</p>Fórmula:C25H17F3N4O3Pureza:98% - 98.25%Cor e Forma:SolidPeso molecular:478.42SAR502250
CAS:<p>SAR502250: potent, selective GSK3 inhibitor, IC50=12nM, oral, brain-penetrant, potential for AD research, antidepressant-like properties.</p>Fórmula:C19H18FN5O2Cor e Forma:SolidPeso molecular:367.38HER2-IN-5
CAS:<p>HER2-IN-5 is an effective inhibitor of orally active HER-2.</p>Fórmula:C27H33N7O3Cor e Forma:SolidPeso molecular:503.6CC214-1
CAS:<p>CC214-1 is an mTOR inhibitor that inhibits protein translation, induces autophagy, and is an in vitro tool compound for exploring the biology of mTOR kinases.</p>Fórmula:C20H21N7O2Pureza:97.16%Cor e Forma:SolidPeso molecular:391.43Antitrypanosomal agent 14
CAS:<p>Antitrypanosomal agent 14 (Compound 1), a potent T.</p>Fórmula:C14H23N3OSPureza:98%Cor e Forma:SolidPeso molecular:281.42A 1070722
CAS:<p>A 1070722: potent GSK-3 inhibitor, Ki = 0.6 nM for both α/β isoforms, crosses BBB, potential brain GSK-3 PET radiotracer.</p>Fórmula:C17H13F3N4O2Pureza:99.9%Cor e Forma:SolidPeso molecular:362.31PT-65
CAS:<p>PT-65, a potent and selective GSK3 degrader, demonstrates the highest degradation capacity for GSK3α (DC50 = 28.3 nM) and GSK3β (DC50 = 34.2 nM) in SH-SY5Y cells, making it applicable for Alzheimer's disease research [1].</p>Fórmula:C51H63N13O12SCor e Forma:SolidPeso molecular:1082.19PI5P4Kα-IN-1
CAS:<p>PI5P4Kα-IN-1 (Compound 13) is a phosphatidylinositol 5-phosphate 4-kinase (PI5P4K) inhibitor, displaying IC50 values of 2 μM for PI5P4Kα and 9.4 μM for PI5P4Kβ</p>Fórmula:C20H17N3O2SPureza:98%Cor e Forma:SolidPeso molecular:363.43PI3K/mTOR Inhibitor-5
CAS:<p>PI3K/mTOR Inhibitor-5 is a potent dual inhibitor of PI3K and mTOR, displaying IC50 values of 86.9 nM (for PI3K) and 14.6 nM (for mTOR), respectively.</p>Fórmula:C32H40N10O3Cor e Forma:SolidPeso molecular:612.73Nazartinib S-enantiomer
CAS:<p>Nazartinib is an EGFR inhibitor. Nazartinib S-enantiomer is the less active S-enantiomer of Nazartinib.</p>Fórmula:C26H31ClN6O2Pureza:98%Cor e Forma:SolidPeso molecular:495.02PI3Kγ inhibitor 2
CAS:<p>PI3Kγ inhibitor 2 is an orally bioavailable inhibitor of PI3Kγ(Ki of 4 nM).</p>Fórmula:C20H18F3N5O3Pureza:98%Cor e Forma:SolidPeso molecular:433.38
